05.04.26 -- Aligning Upstream And Downstream Development (Part 1)

Non-viral gene editing is a powerful method for cell therapy. Learn how to address key challenges like cell viability and thermal damage with an innovative approach designed to improve performance.

Advancements in high-sensitivity residual DNA testing enhance the precision of plasmid DNA purity analysis, ensuring compliance with regulatory standards critical for manufacturing processes.

Learn about the defining criteria and varied tissue sources of MSCs. Discover their expanding role in therapies targeting inflammatory conditions and tissue regeneration.

Small-scale perfusion-mimic models can effectively predict media performance in continuous bioreactors to help optimize cell density, productivity, and scalability for CHO cell lines.

Cryopreservation enables cell therapy by storing cells long-term. A DMSO-free formula preserves cell viability and health, minimizing toxicities linked with traditional cryoprotectants.

Transferring cell cultures between scales is challenging and error-prone. Uncover a bioreactor scaling software that predicts optimal settings to enable efficient scale-up and progression to clinical studies.

Explore various strategies to enhance viral titer and increase the percentage of full AAV capsids, like modifications to transfection reagents, cell lines, media, procedures, and more.

Transposons are an efficient and cost-effective method for gene transfer in cell engineering and therapies. Their delivery can be optimized to improve cell expansion and functionality.

Peptones offer a valuable tool for optimizing cell culture. By carefully selecting and using peptones, biopharmaceutical manufacturers can improve the efficiency, productivity, and quality of a process.